ABERDEEN, Scotland and Singapore, 22nd July 2016 – TauRx Therapeutics Ltd recently completed its Phase III clinical trial of the company’s second generation tau aggregation inhibitor, LMTX®, in behavioural variant frontotemporal dementia (bvFTD), believed to be the largest Phase III study ever undertaken in patients with this rare neurodegenerative disorder. Public disclosure of the study results will be delayed for a few weeks in order to permit the company to protect intellectual property arising from the on-going analysis of the patient data. The results of this trial, originally planned for presentation at the 2016 Alzheimer’s Association International Conference (AAIC) in Toronto, will now be reported for the first time at the 10th International Conference on Frontotemporal Dementias (ICFTD) in Munich on 31 August-2 September 2016.
Read more here.
TauRx Therapeutics Ltd recently completed its Phase 3 clinical trial of the company’s second generation tau aggregation inhibitor, LMTX® , in behavioural variant frontotemporal dementia (bvFTD)
